Amphastar Pharmaceuticals Enters into Contract Research Agreement with Nanjing Hanxin

On September 15, 2025, Amphastar Pharmaceuticals, Inc. entered into a contract research agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. Under this agreement, Hanxin will develop Recombinant Peptide Research Cell Banks (RCBs) for Amphastar and license these RCBs to the company. The RCBs will be used to create Master Cell Banks for Amphastar's product candidate, AMP-107. The agreement grants Amphastar a fully paid, exclusive, perpetual, transferable, and sub-licensable license worldwide. Hanxin is required to keep Amphastar informed of the development and research progress. The total cost of the agreement is approximately $2.8 million, with an initial payment of $0.3 million. The agreement term is three years. The independent and disinterested members of Amphastar's Audit Committee approved the agreement, considering the beneficial ownership of Hanxin by Amphastar's CEO, President, and Chairman.